Abstract
Sericin, a natural protein derived from Bombyx mori, is known to ameliorate liver tissue damage; however, its molecular mechanism remains unclear. Herein, we aimed to identify the possible novel targets of sericin in hepatocytes and related cellular pathways. RNA sequencing analysis indicated that a low dose of sericin resulted in 18 differentially expressed genes (DEGs) being upregulated and 68 DEGs being downregulated, while 61 DEGs were upregulated and 265 DEGs were downregulated in response to a high dose of sericin (FDR ≤ 0.05, fold change > 1.50). Functional analysis revealed that a low dose of sericin regulated pathways associated with the complement and coagulation cascade, metallothionine, and histone demethylate (HDMs), whereas a high dose of sericin was associated with pathways involved in lipid metabolism, mitogen-activated protein kinase (MAPK) signaling and autophagy. The gene network analysis highlighted twelve genes, A2M, SERPINA5, MT2A, MT1G, MT1E, ARID5B, POU2F1, APOB, TRAF6, HSPA8, FGFR1, and OGT, as novel targets of sericin. Network analysis of transcription factor activity revealed that sericin affects NFE2L2, TFAP2C, STAT1, GATA3, CREB1 and CEBPA. Additionally, the protective effects of sericin depended on the counterregulation of APOB, POU2F1, OGT, TRAF6, and HSPA5. These findings suggest that sericin exerts hepatoprotective effects through diverse pathways at different doses, providing novel potential targets for the treatment of liver diseases.
Similar content being viewed by others
Introduction
The liver is a vital organ in the human body. They are organized as a structurally diverse group of specialized tissues that are involved in crucial biochemical functions. It can be broadly defined as metabolic, exocrine, and endocrine in nature. It also regulates functions involving detoxification, hormone production, decomposition of red blood cells, protein anabolism and nutrient metabolism1. Hepatotoxicity is defined as liver injury caused by chemical or drug abuse, excessive alcohol consumption, infections, or autoimmune disorders that results in impaired liver function2,3,4. Despite tremendous strides in modern medicine, there are few available drugs that effectively restore liver function, exert hepatoprotective effects or promote the regeneration of hepatic cells. However, natural extracts are gaining increasing attention as pharmacotherapeutic agents for the treatment of liver diseases due to their improved efficacy and safety compared to the currently used drugs. The use of natural medicine for the treatment of liver diseases has a long history, and their therapeutic effects are achieved by targeting multiple factors and pathways. Several studies have shown that natural extracts protect against CCl4-related hepatotoxicity by improving antioxidant enzyme activity and suppressing lipid peroxidation5,6.
Sericin is a natural protein produced by the silkworm Bombyx mori (B. mori), a holometabolous insect belonging to the Bombycidae family in the Lepidoptera order. B. mori produces sericin and, together with fibroin, creates silk thread to form cocoons7. Due to its variety of biological properties, including antioxidation, anti-inflammatory and anticancer properties, sericin has been extensively used as a medical drug8. It has been used to treat and prevent liver injury, diabetes, cardiovascular diseases, skin diseases, and neurological diseases9,10,11,12. Sericin is also known to interact with several molecular targets underlying its pharmacological effects against diseases8. You-Gui Li et al. revealed that sericin protects against lipid peroxidation in membranous organelles by upregulating superoxide dismutase (SOD), catalase (CAT), and plasma glutathione peroxidase (GSH-PX) enzymes in the liver13. Chengjun Song et al. showed that sericin was able to increase the signal transduction effect of insulin by increasing the expression levels of key factors involved in insulin resistance (IR), such as insulin receptor substrate-1 (IRS-1), phosphatidylinositol-3-kinase (PI3K) and AKT, in the liver insulin-PI3K/AKT signaling pathway, thereby promoting the synthesis of hepatic glycogen14. Ampawong et al. demonstrated that sericin balances pancreatic cell biosynthesis by enhancing lipid dysregulation in hypercholesterolemia, resulting in a reduction in dysmorphic mitochondria, particularly in the heart and liver15. Heng-Da Wang et al. suggested that sericin effectively decreases inflammatory infiltration, restores impaired liver cells, and repairs liver damage16. Although sericin has been reported to ameliorate pathological damage in liver tissue and has a hepatoprotective effect against liver damage, systematic investigations of the molecular mechanisms by which sericin prevents liver diseases are incomplete.
Next-generation sequencing-based transcriptome profiling is a powerful approach for interpreting the molecular mechanisms underlying biological processes17 and has been widely applied in drug discovery and development to identify drug-associated genes18. Using RNA sequencing (RNA-seq) and gene expression analysis, this study aimed to identify candidate genes and promising targets of sericin in order to generate a novel hypothesis on the molecular mechanism of action of sericin in relation to various human liver diseases, including viral hepatitis, liver cirrhosis, and hepatocellular carcinoma. The results of the Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome database analyses, the protein‒protein interaction network analysis (PPIN) and the transcription factor activity analysis, highlighted several biological processes modulated by sericin. This transcriptome analysis provides new insight into the regulatory and beneficial effects of sericin on hepatic cells.
Results
Assessment of the cytotoxic effect of sericin on HepG2 cells
The cytotoxic effect of sericin was assessed in HepG2 cells using an MTT assay. The concentrations of sericin used in this study were 0, 0.125, 0.25, 0.5, and 1 mg/mL. The results showed no cytotoxicity following sericin administration (Fig. 1). Hence, we selected a low concentration (0.125 mg/mL) and a high concentration (1 mg/mL) of sericin for the subsequent RNA-seq analysis.
Identification of differentially expressed genes (DEGs)
After the hepatic cells were treated with low (0.125 mg/mL) or high (1 mg/mL) concentrations of sericin, hierarchical clustering was performed to establish the impact of different concentrations of sericin on the transcriptome. Hierarchical clustering was performed for the untreated sericin or control (n = 3), 0.125 mg/mL sericin-treated (n = 3) and 1 mg/mL sericin-treated (n = 3) groups. The transcriptome of each group was normally segregated based on the sericin-treated group (Supplementary Fig. S1). A total of 60,606 transcripts were identified. Of the 86 DEGs, 18 were upregulated, whereas 68 were downregulated in the 0.125 mg/mL sericin group compared with the untreated group. The volcano plots showed that the number of DEGs between the 1 mg/mL sericin-treated group and the untreated group differed from that between the 0.125 mg/mL sericin-treated group and the untreated group. Three hundred twenty-six (326) genes exhibited significant alterations in gene expression. Among them, 61 DEGs were upregulated and 265 DEGs were downregulated. Interestingly, 31 DEGs were found between the 0.125 mg/mL treatment group and the 1 mg/mL treatment group. There were 12 upregulated genes and 19 downregulated genes (padj ≤ 0.05, fold change > 1.5) (Table 1, Fig. 2, and Supplementary Table S1).
Furthermore, the shared DEGs associated with sericin administration were analyzed via a Venn diagram (Fig. 3). The 0.125 mg/mL sericin-treated group and the 1 mg/mL sericin-treated group shared 5 upregulated and 33 downregulated genes. In contrast, there were 4 unique upregulated genes and 14 unique downregulated genes between the 0.125 mg/mL group and the 1 mg/mL group. These genes, as demonstrated by our findings, are strongly associated with hepatic protection.
Functional enrichment analysis
GO analysis
GO analysis was performed using the hypergeometric distribution to functionally annotate the DEGs. GO terms were analyzed for both the 0.125 mg/mL sericin group and the untreated and 1 mg/mL sericin group and untreated groups. The 86 DEGs identified in the 0.125 mg/mL sericin treatment group vs. the untreated group were enriched in 42 GO biological process terms. (Supplementary Table S2). The top three significantly enriched GO terms were positive regulation of T-helper 1 cell cytokine production, positive regulation of transcription from RNA polymerase II promoter in response to hypoxia and negative regulation of smooth muscle cell migration. On the contrary, GO terms. In contrast, GO term analysis of the 326 DEGs identified in the 1 mg/mL sericin group revealed 90 enriched GO terms (Supplementary Table S3). The top three considerably enriched GO terms were nuclear speck, negative regulation of transcription from DNA template, and RNA polymerase II cis-regulatory region sequence-specific DNA binding. Interestingly, GO analysis of the DEGs between the 0.125 mg/mL and 1 mg/mL groups revealed that these DEGs were enriched in protein refolding, G protein-coupled receptor binding and heat shock proteins (Supplementary Table S4).
KEGG and reactome pathway analysis
The biological interpretation of the DEGs was further achieved using the KEGG and Reactome databases. KEGG pathway enrichment and Reactome analyses were performed to identify the functions of the DEGs. In 0.125 mg/mL sericin vs. untreated group, the significant DEGs (padj < 0.01, fold change > 1.5) were mapped to the KEGG and Reactome databases (Fig. 4, and Supplementary Table S5). The four significantly enriched KEGG pathways involved complement and coagulation cascades, glutathione metabolism, atherosclerosis, and apoptosis. Among them, the upregulation of members of the complement and coagulation cascades pathway (A2M, SERINA5) was observed only in the low-dose group. In addition, the two novels significantly enriched Reactome pathways included the intrinsic pathway of fibrin clot formation (A2M, SERPINA5), metallothionein-binding metals, and response to metal ions (MT2A, MT1G, MT1E). Interestingly, the presence of metallothionein-binding metals and the response to metal ions were correlated with glutathione metabolism, which was found in the KEGG analysis.
Among the 1 mg/mL sericin-treated vs. untreated strains, the two most enriched KEGG pathways included the MAPK signaling pathway (TRAF6, HSPA8) and lipid and atherosclerosis (POU2F1, APOB) pathways, whereas the four most enriched Reactome pathways involved selective autophagy, macroautophagy, autophagy (MAP1LC3B, DYNC1H1, HSPA5), and signal transduction by growth factor receptors and second messengers. Among the significantly enriched Reactome pathways, selective autophagy, microautophagy, and autophagy were regulated upon sericin administration. This observation suggested that sericin may have a modulatory impact on hepatocellular carcinoma cells. (Fig. 5, and Supplementary Table S6).
The results for the common differentially expressed genes (DEGs) in both the 0.125 mg/mL treatment group and the untreated and 1 mg/mL treatment groups compared with the untreated sericin treatment group revealed that histone modification was a crucial pathway (Fig. 6A). The O-GlcNAc transferase (OGT) gene was identified as a key player in several significantly enriched pathways among these common DEGs. This pattern suggested a threshold effect in which sericin at both tested concentrations triggered a uniform cellular response involving OGT, indicating an inherent protective mechanism. The consistent presence of OGT among the DEGs of both the low-dose and high-dose sericin groups underscores its role in activating important cellular pathways, thereby highlighting the potential of sericin for effective hepatoprotection. KEGG and Reactome enrichment analyses were performed on the HSPA8 and HSPA1A genes, which were differentially expressed between the 0.125 mg/mL and 1 mg/mL sericin treatment groups. These genes were notably involved in pathways such as HSF-dependent transactivation and the HSP90 chaperone cycle (Fig. 6B,C, and Supplementary Table S7). This discovery emphasizes the crucial role of sericin dosage in modulating stress response pathways and highlights its dose-specific influence on hepatoprotective mechanisms.
,
Protein–protein interaction network (PPIN) analysis
To explore the potential interactions at the protein level, DEGs were mapped in Biogrid, and a PPI network was constructed for DEGs in different groups at a stringent cutoff. The PPI network showed that the DEGs between the 0.125 mg/mL and untreated groups, the 1 mg/mL and untreated groups and the 0.125 mg/mL and 1 mg/mL groups, as well as the related functions and pathways identified by the GO, KEGG, and Reactome analyses, were correlated. Interestingly, all genes in the network are involved in the intrinsic pathway of fibrin clot formation and metallothionine binding metals, with autophagy emerging as a novel network aspect (Fig. 7).
Expression of key genes involved in the hepatoprotective mechanisms of sericin
The differential expression of key genes associated with sericin administration was identified via KEGG, Reactome, and PPIN pathway analyses (Figs. 3, 4, 5, 6, 7). The key genes associated with the interesting and novel pathways are highlighted. At 0.125 mg/mL sericin vs. untreated, there were seven upregulated genes (RRM2, ODC1, GCLM, SERPINE1, MT2A, MT1G, MT1E) related to glutathione metabolism and complement, coagulation cascades, metallothionine-binding metals and the response to metal ions. In contrast, there were five downregulated DEGs (BCL6, PAQR8, A2M, SERPINA5, F5) related to chemical carcinogenesis-receptor activation, complement and coagulation cascades. Interestingly, A2M and SERPINA5 were found to be shared genes according to the KEGG and Reactome enrichment analyses. At 1 mg/mL sericin vs. untreated, there were 17 downregulated DEGs (HSPA1A, HSPA8, DDIT3, PIK3R1, PPP3CA, TRAF6, ABCA1, POU2F1, APOB, MAPK8IP3, TAOK2, MAP3K2, FGFR1, DYNC1H1, HSPA5, PRKAB2, DCNT) that are were involved in lipid metabolism and atherosclerosis, the MAPK signaling pathway, selective autophagy, microautophagy and autophagy in hepatic cells, while 4 genes (MAP1LC3B, MAP1LC3B, RRS27A, TOMM5) associated with autophagy were upregulated. Furthermore, key genes identified via GO analysis are listed in Supplementary Tables S2 and S3.
Identification of transcription factors
Transcription factors play vital roles in several gene regulatory mechanisms. The transcription factors associated with the DEGs were identified to further investigate the regulatory mechanisms of sericin in HepG2 cells. To define TF activity as a marker of therapeutic response, dcoupleR was used to statistically analyze gene expression and map the genes to the DoRothEA regulon gene set. The total activity score generated by dcoupleR represented the degree to which TFs regulated the gene expression network.
A bar plot of the changes in transcription factor (TF) activity upon treatment with 0.125 mg/mL sericin was constructed, which revealed eleven significant TFs. One TF, NFE2L2 (NFE2-like bZIP transcription factor 2), was activated and the following TFs were deactivated: CEBPA (CCAAT enhancer binding protein alpha), STAT1 (signal transducer and activator of transcription 1), SOX2 (SRY-box transcription factor 2), FOS (fos proto-oncogene or AP-1 transcription factor subunit), TFAP2C (transcription factor AP-2 gamma), FOXO1 (forkhead Box O1), STAT3 (signal transducer and activator of transcription 3), GATA3 (GATA binding protein 3), GATA2 (GATA binding protein 2) and TAL1 (TAL bHLH transcription factor 1) (Fig. 8). Notably, the activity of hepatic NFE2L2, a master regulator of the oxidative response, was increased upon low-dose sericin treatment. Investigating individual genes within the NFE2L2 TF regulon revealed the greatest increase in expression upon low dose sericin treatment in IL1R1, SORBS1, RREB1, GCLM, TXNRD1, and SQSTM1. These genes, which respond to detoxifying and antioxidant challenges in oxidative stress, exhibit cytoprotective effects, thereby preventing hepatic inflammation and injury by counteracting cytotoxicity. (Supplementary Fig. S2). In contrast, the most significant TF that exhibited a decrease in TF activity upon low-dose sericin treatment was CEBPA, which is involved in cellular differentiation, growth, and energy metabolism. Activation of CEBPA was indicated by decreased expression of the ARIDB5, FILPP1L, NFIL3, ZBTB38, IL1R1, NEDD9, TGFBR3, MMD, PTCHD4, KANK1 and PAQR8 genes as well as overexpression of MRPL3, which ameliorated liver injury and inflammation (Supplementary Fig. S2). These analyses revealed that CEBPA, NFE2L2 and their downstream target genes are important modulators of hepatoprotection upon low-dose sericin treatment. In addition, the significant changes in the expression of the TFs inferred from their regulon at 1 mg/mL were associated with the active TF NFE2L2 and the deactivated TFs CREB1 (cAMP responsive element binding protein 1), TFAP2 (transcription factor AP-2 gamma), PRDM14 (PR/SET domain 14), RELA (RELA proto-oncogene or NF-kB subunit), MITF (melanocyte inducing transcription factor), NFIC (nuclear Factor I C), SP1 (Sp1 transcription factor), GATA3 (GATA binding protein 3), TAL1 (AL bHLH transcription Factor 1), and STAT1 (signal transducer and activator of transcription 1) (Fig. 8). Notably, the network of NFE2L2 TF regulon (PLEC, RREB1, CHD9, TXNRD1, GSTQ, GCLM, TGIF1 and NCOA7) exhibited the highest increase of NFE2L2 TF activity (Supplementary Fig. S3). Deactivation of TF CREB1 has been described in fibrogenesis, and its activity was considerably decreased upon high-dose sericin treatment. The activity of CREB1, as inferred from changes in the expression of its regulon, involved alterations in FN1, EGR1, FAT1, URTN, CHD9, and RREB1 (Supplementary Fig. S3). Interestingly, four pioneer TFs, STAT1, TFAP2C, GATA3 and NFE2L2, were affected by sericin treatment. Among these TFs, NFE2L2 was the activated, while STAT1, TFAP2C and GATA3, involved in inflammatory and lipid metabolism, were the deactivated upon sericin treatment.
Effect of sericin on acetaminophen-induced hepatotoxicity
The cytotoxicity of acetaminophen (APAP) was assessed in HepG2 cells via MTT assay. Cell viability decreased with increasing APAP concentrations (2.5–40 mM), showing more than 30% and 40% reductions at 5 mM and 10 mM, respectively (Supplementary Fig. S4). The IC50 was 4.2 mM. Co-treatment with APAP and sericin mitigated APAP-induced cell death in a dose-dependent manner (Fig. 9). Both high and low concentrations of sericin significantly reduced cell death in the presence of 10 mM APAP but were less effective in the presence of 5 mM APAP. As a result, 5 mM and 10 mM APAP were selected for further studies on the hepatoprotective effects of sericin.
To validate the hepatoprotective effects of sericin, gene expression assays were conducted in the presence of varying concentrations of APAP and sericin. Multiple regression analysis revealed that APOB, TRAF6, POU2F1, OGT, and HSPA5 expression correlated significantly with both treatments (Table 2 and Fig. 10), underscoring the potential role of sericin in counteracting APAP-induced hepatotoxicity via gene modulation. Additionally, the changes in TRAF6 expression in response to different treatments provide insights into the protective effects of sericin against APAP-induced hepatotoxicity. After treatment with 0.125 mg/ml sericin, TRAF6 expression did not change, indicating a lack of direct effect at this concentration. However, when hepatotoxicity was induced using APAP, the same concentration of sericin led to a notable alteration in TRAF6 expression. Intriguingly, a higher sericin dose of 1 mg/mL upregulated TRAF6 but not to the same extent. These findings suggested that while sericin can modulate gene expression in a dose-dependent manner, its hepatoprotective effects become more pronounced under stress conditions, such as those induced by APAP.
Verification of transcriptomic data by RT‒PCR
To further evaluate the accuracy of the RNA-Seq transcriptome data, ten candidate DEGs with a stringent cutoff (p < 0.01) were selected from both the 0.125 mg/mL sericin vs. untreated and 1 mg/mL sericin vs. untreated groups. This selection included upregulated genes, such as SLC16A; downregulated genes, namely ARID5, BCL6, EGR1, KLHL14, SERPINA3, TCIM, TPM2, TRAF6, and YPEL2, all of which are involved in different functional pathways. The expression levels of the selected DEGs were measured using qRT-PCR. Results exhibited the expression of SLC16A6 was upregulated and expression of ARID5, BCL6, EGR1, KLHL14, SERPINA3, TCIM, TPM2, TRAF6, and YPEL2 were downregulated in a dose-dependent manner (Fig. 11, Supplementary Table S8). To ensure the reliability of our RNA-seq results, we conducted qPCR validation for all the genes mentioned in this study (Supplementary Table S9). While there were variations in the degrees of fold change, the majority of the genes exhibited consistent differential expression in the same direction, reinforcing the validity of our findings.
Discussion
Despite tremendous advances in modern medicine, there are few available drugs that effectively improve liver function or protect against liver damage. Sericin is a natural product that has remarkable antioxidant, anti-inflammatory and anticancer properties and has been extensively used to treat various diseases7. Due to the limited information on the extensive effects of sericin on the transcriptome, RNA-seq was utilized to reveal the DEGs and cellular pathways affected by sericin in HepG2 cells. These data not only confirm the hepatoprotective effect of sericin but also reveal several novel genes in different cellular pathways that are regulated by sericin in HepG2 cells. To evaluate the cytotoxicity of sericin, cells were treated with different concentrations of sericin (0, 0.125, 0.25, 0.5, 1 mg/mL). Sericin was not toxic to HepG2 cells. Due to the nontoxicity of sericin, a low concentration (0.125 mg/mL) and a high concentration (1 mg/mL) were selected for the subsequent transcriptome analysis. The RNA-seq analysis detected 60,600 transcripts in the sericin-treated HepG2 cells. DEG analysis, pathway enrichment analyses (GO, KEGG, Reactome), and network analysis (PPIA) were used to compare gene regulation among the HepG2 cell groups (0.125 mg/mL vs. untreated, 1 mg/mL vs. untreated, and 1 mg/mL vs. 0.125 mg/mL).
In the 0.125 mg/mL sericin group, numerous enriched pathways were detected, such as the coagulation cascade pathway (A2M, SERPINA5), metallothionein binding metal pathway and response to metals (MT2A, MT1G, MT1E) and HDM demethylate histone pathway (ARID5B, KDM7A, KDM6B); these altered pathways exhibited the potent hepatoprotective activity of sericin. Moreover, BCL6 was found to be a novel target of low-dose sericin treatment. A2M, alpha-2-macroglobulin, is a proteinase inhibitor that inactivates several proteinases and suppresses fibrinolysis by reducing plasmin and kallikrein. Previous studies have reported that an increase in A2M suppresses the catabolism of matrix proteins that cause liver fibrosis19. Gangadharan B et al. demonstrated that thioester cleavage of A2M increases slowly with the development of fibrosis20. In the present study, downregulation of A2M might reduce liver fibrosis, suggesting that A2M is a novel biomarker target of sericin. SERPINA5, Serine Proteinase Inhibitor Clade A Member 5, is a major anticoagulant protease that can suppress activated protein C. Fan et al. showed that SERPINA5 enhances tumor cell proliferation by regulating the PI3K/AKT/mTOR signaling pathway in gastric cancer21. Zhang et al. revealed that SERPINA5 was upregulated in liver metastatic cancer tissues22. These findings support our findings that the downregulation of SERPINA5 might be associated with a reduction in liver damage and the alleviation of liver cancer. Interestingly, the expression of genes encoding metallothionein was upregulated upon low-dose sericin administration. Metallothionein is a cysteine-rich protein that plays a vital role in metal homeostasis, heavy metal toxicity, DNA damage and oxidative stress protection. Abnormal expression of metallothionein genes is noted in several cancers and is related to tumor formation, metastasis, drug resistance and poor prognosis. Previous studies have shown that metallothionein 2A (MT2A) is downregulated in gastric cancer cells and exerts its anti-gastric cancer effect by binding to MZF1 to target NFKBIA23. In hepatoma cells, MT2A is also downregulated and plays a cancer suppressive role24. In addition, metallothionein 1G (MT1G) is reduced in human HCC tissues due to promoter hypermethylation25, and metallothionein 1E (MT1E) is downregulated in hepatocellular carcinoma (HCC), which induces apoptosis and suppresses the metastasis of HCC26. These findings are consistent with our study in that an increase in the expression of metallothionein genes might indicate an anticancer effect of sericin. Histone demethylases are involved in regulating cellular processes such as chromatin structure and transcription27. Kim et al. revealed that overexpression of the histone demethylase KDM7A induces hepatic steatosis via upregulation of DGAT2 by erasing H3K9me2 and H3K27me2 on the promoter28. Tang et al. reported that the histone demethylase KDM6B promotes epithelial–mesenchymal transition, migration, invasion, and stemness in HCC29. He et al. showed that the upregulation of AT-rich interaction domain 5B (ARID5B) is associated with the activation of hepatic stellate cells, which leads to liver fibrosis30. These results suggested that the downregulation of genes related to histone demethylation might play a role in the hepatoprotective effect of sericin.
Surprisingly, administration of 1 mg/mL sericin promoted pathways involved in lipid metabolism and atherosclerosis, MAPK signaling, selective autophagy, microautophagy, and autophagy. Accordingly, the POU2F1 and APOB genes involved in lipid metabolism were downregulated in sericin-treated cells. POU domain class 2 transcription factor 1 (POU2F1) is a ubiquitous transcription factor that regulates the transcription of target genes related to the cell cycle31. Zhong et al. reported that POU2F1 overexpression is positively related to aggressive phenotypes and poor survival in patients with HCC. POU2F1 is modulated by the AKT pathway and promotes aggressive HCC phenotypes by regulating the transcription of epithelial-to-mesenchymal transition genes32. Zhu et al. reported that POU2F1 enhances the growth and metastasis of HCC via the FAT1 signaling pathway33. These previous findings support our findings that downregulation of POU2F2 might alleviate HCC. Apolipoprotein B (APOB) plays a critical role in human lipoprotein metabolism. Gudowska et al. reported that an increase in APOB is associated with viral hepatitis and alcoholic cirrhosis34. Crooke et al. demonstrated that suppression of APOB by antisense oligonucleotides reduced LDL cholesterol without causing hepatic steatosis35. This result aligns with our finding that a lower APOB might decrease the release of triglyceride-rich lipoprotein, thereby ameliorating hepatic steatosis. In addition, the gene pathway annotation network revealed that TRAF6, HSPA8, and FGFR1, which are involved in MAPK signaling, were downregulated. TNF receptor associated factor 6 (TRAF6) is a key mediator of NF-κB signaling and is related to the IL-1R/TLR pathway and restrains the phosphorylation of IκBα36. Once activated, TRAF6 initiates an inflammatory cascade amplification, leading to tissue damage and organ dysfunction37. Therefore, the downregulation of TRAF6 suggested that sericin could reduce the inflammatory cascade and protect the liver from damage. Heat shock protein 70 (HSP70) and its major cochaperones, including cytosolic HSPA8, are related to various phenotypes of tumorigenesis, including proliferation, invasion, and metastasis38. Consistent with our study, downregulating HSPA8 upon sericin treatment possibly helps to prevent liver cancer. Fibroblast growth factor receptors (FGFRs) are master mediators of a broad spectrum of cellular and developmental processes involving apoptosis, proliferation, and angiogenesis. FGFR1 has been reported to promote both hepatic stellate cell (HSC) activation and proliferation39. This report correlates with our findings that FGFR1 downregulation upon sericin treatment might suppress HSC activation. Notably, sericin regulates autophagy-related genes (MAP1LC3B, DYNC1H1 and HSPA5). Autophagy is a cellular process that removes polyubiquitinated protein aggregates and mitochondria40. Microtubule-associated protein 1 light chain 3 (MAP1LC3B) is a major marker of autophagy that acts as an autophagy receptor for autophagosome elongation in mammalian cells41. Yu et al. demonstrated that low expression of MAP1LC3B predicts lymph node metastasis and poor prognosis in gastric cancer patients42. Dynein cytoplasmic 1 heavy chain 1 (DYNC1H1) is a protein-coding gene encoding the cytoplasmic dynein heavy chain family. Wang et al. reported that DYNC1H1 expression influences liver hepatocellular carcinoma initiation and progression and the immune microenvironment43. Yang et al. indicated that high levels of HSPA5 are associated with earlier recurrence of HCC44. Notably, high-dose sericin administration attenuated the expression of liver-associated disease genes, which was accompanied by, at least, upregulation of MAP1LC3B and downregulation of DYNC1H1 and HSPA5, which are autophagy-related genes.
Notably, one gene that regulates lipid metabolism and atherosclerosis pathways was affected by sericin at 0.125 mg/mL to 1 mg/mL. The O-linked β-N-acetylglucosamine transferase (OGT) is responsible for the addition of GlcNAc moieties to select serine and threonine residues on nuclear and cytosolic proteins and is involved in a number of cellular functions. Alterations in OGT have been found to be related to many pathologies, such as diabetes, cardiovascular disease, neurodegeneration and cancer45. Lynch et al. showed that OGT levels are usually increased in cancer. A decrease in OGT in cancer cells leads to growth reduction and metastasis46. This study supported our findings that the downregulation of OGT upon sericin administration at both high and low doses might reduce liver-associated diseases.
The TFs obtained from the DEGs were identified to further study the molecular regulatory network activated or deactivated by sericin administration. Alterations in TF activity were calculated using DEG data. Based on the TF activity prediction, numerous transcription factor genes and their downstream targets were shown to be associated with cellular differentiation, cell proliferation, the inflammatory response, oxidative stress and lipid metabolism and were affected by both low and high doses of sericin. This finding suggested the modulation of crucial biological functions, potentially alleviating liver injury. CEBPA, STAT1, TFAP2C and GATA3 TFs were predicted to be deactivated, while the NFE2L2 TF was predicted to be activated upon low-dose sericin administration. CEBPA, a TF belonging to the CCAAT/enhancer-binding protein family, plays a vital role in hepatic glucose and lipid homeostasis as well as in the maintenance of cell proliferation47,48. Interestingly, the NFE2L2 TF was also predicted to be activated upon high-dose sericin administration. Similarly, deactivation of the STAT1, TFAP2C and GATA3 TFs was observed upon sericin administration. In contrast, only the CREB1 TF exhibited a difference in expression pattern following low-dose sericin administration. Previous studies have shown that CEBPA-null mice exhibit glucose intolerance, decreased serum cholesterol levels, and hepatic steatosis47. Strikingly, CEBPA has been reported to be upregulated in a subset of HCCs and to have growth-promoting effects on HCC cells49. These opposing roles of CEBPA in HCC cell subsets may be determined by epigenetic regulatory mechanisms50. This trend is consistent with our study, which indicated that cell growth decreased due to reduced CEBPA expression. STAT1 is a central signaling constituent of IFN and plays vital roles in antitumor activity, antiviral defense, induction of liver injury and inflammation and inhibition of liver regeneration51. Accumulated research data suggest that suppression of hepatic STAT1 activation through genetic modification of various genes prevents concanavalin A-induced liver injury52,53. These findings support our findings that deactivation of STAT1 upon sericin administration may ameliorate liver inflammation and liver injury. TFAP2C, a member of the AP2 transcription factor family, is critical for maintaining cellular homeostasis; regulating proliferation and apoptosis; and promoting embryonic development54. A previous study revealed that transgenic overexpression of Tcfap2c in the liver promoted proliferation and apoptosis and induced hepatic steatosis, leading to liver failure55. Hence, we speculated that the deactivation of the TFAP2C TF upon sericin administration might suppress proliferation, reduce hepatic steatosis and subsequently alleviate liver damage. GATA3, a member of the GATA family, plays a crucial role in inflammatory and humoral immune responses56. Its expression was previously shown to be associated with impaired adipogenesis, and it contributes to the induction of inflammatory cytokine production in adipose tissue57. The inhibition of GATA3 expression improved adipocyte differentiation, reduced inflammation and reversed insulin resistance58. In addition, suppression of GATA3 increased the mRNA and protein levels of lipase A, which serves as a biomarker of liver fibrosis59. Our study indicated that the GATA3 TF is likely deactivated upon sericin administration, consistent with the findings of previous research. Therefore, we inferred that sericin might exert its anti-liver fibrosis effect by targeting GATA3 and reducing inflammatory molecules in the liver. NFE2L2 plays a role in activating the oxidative stress defense mechanism by promoting antioxidant and detoxifying enzymes to prevent cells from diverse oxidative insults60. Many studies have reported that the hepatoprotection mechanism against oxidative stress-induced HCC primarily involves the modulation of various genes, including those involved in glutathione biosynthesis, which prevents oxidative damage61,62. These findings support our study, suggesting that sericin significantly activates NFE2L2 TF in the HepG2 cell line, indicating that its hepatoprotective effects can be attributed to its antioxidant effects. CREB1 is involved in gene regulation in response to various extracellular signals63, and its transcriptional activity is modulated by Ser133 phosphorylation64. Previous studies have implicated CREB1 in fibrogenesis. It facilitates high glucose-promoted renal tubulointerstitial fibrosis in diabetic nephropathy65. Additionally, activation of CREB1 is markedly increased in CCl4-induced liver fibrosis66, and in alcoholic liver fibrosis67. Thus, our finding of predicted deactivation of the CREB1 TF upon sericin treatment aligns with the findings of previous studies suggesting that downregulation of CREB1 may contribute to the recovery of hepatic fibrosis. To this end, these analyses showed that sericin could alleviate liver injury by modulating transcription factor activity.
This study further revealed that sericin significantly mitigated APAP-induced cell death in HepG2 cells, a known effect of APAP, as documented in previous studies68. Sericin also modulates the expression of genes linked to lipid metabolism (POU2F1, APOB, OGT), MAPK signaling (TRAF6), and autophagy (HSPA5). Notably, the ability of sericin to counteract APAP-induced damage was evident in its regulation of key genes, with a pronounced effect on TRAF6 expression, which is typically upregulated in response to liver injury69. Taken together, our findings on sericin are the first to show that sericin has many hepatoprotective effects on hepatocytes, promoting liver function and alleviating liver-associated diseases.
Conclusions
A hepatic transcriptome analysis showed that sericin administration leads to significant transcriptional changes in human hepatocellular carcinoma cells. Computational analysis revealed the effects of sericin at various doses: a lower dose influenced the complement and coagulation cascades, metallothionine metal binding, and histone demethylase activity, whereas a higher dose affected lipid metabolism, atherosclerosis, MAPK signaling and autophagy. Gene network analysis revealed novel targets, highlighting transcription factors involved in the effects of sericin and confirming its protective effects. Collectively, these findings demonstrate the potent hepatoprotective effects of sericin via multiple pathways, offering valuable insights for therapeutic drug development.
Materials and methods
Sericin extraction
Silkworm cocoons (Bombyx mori) were obtained from Chul Thai Silk Co., Ltd., Phetchabun Province, Thailand. Sericin was extracted from fresh cocoon shells by autoclaving in purified water at 120 °C for 60 min. The supernatant was collected, filtered, frozen, and then lyophilized.
Cell culture and viability assessment
HepG2 cells (ATCC, HB8065, USA) were maintained in DMEM supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 µg/mL streptomycin at 37 °C and 5% CO2 in a humidified environment. For detachment, the cells were incubated with trypsin. A sericin stock solution was prepared in distilled water, while acetaminophen (APAP) (Tylenol, Johnson & Johnson, Thailand) was dissolved in absolute ethanol. These stock solutions were subsequently added to the culture medium to reach the desired concentrations. The effect of sericin on HepG2 cell viability was evaluated using the MTT assay. Cells were seeded in 96-well plates and allowed to incubate for 24 h. Subsequently, the cells were treated with various concentrations of sericin (0, 0.125, 0.25, 0.5, or 1 mg/mL) and APAP (0, 2.5, 5, 10, or 20 mM) for an additional 24 h. After treatment, the medium was discarded, and each well was incubated with MTT solution (5 mg/mL) for 4 h. The formazan crystals that formed were dissolved in 100 µL of DMSO per well. The absorbance was subsequently measured at 570 nm using a spectrophotometer.
RNA isolation
Total RNA was isolated from the HepG2 cells using the RNeasy Mini Kit (Qiagen GMBH, Hilden, Germany) according to the manufacturer’s instructions, yielding approximately 20 μg of total RNA. The amount of total RNA was determined using a NanoDrop™ 8000 spectrophotometer (Thermo Fisher Scientific, USA). The quality of the RNA preparation was evaluated using an Agilent RNA 6000 Nano Kit on an Agilent Bioanalyzer 2100 system (Agilent, Palo Alto, CA). RNA samples with an integrity number (RIN) greater than 9.0 (and a 28S/18S ratio ranging from 1.8 to 2.2) were used for library construction.
mRNA library preparation and sequencing
Total RNA (1 μg) was used for subsequent library preparation. Poly(A) mRNA isolation was performed using oligo (dT) beads. mRNA fragmentation was carried out using divalent cations and at high temperature. Priming was performed using random primers. First-strand cDNA and second-strand cDNA were synthesized. The purified double-stranded cDNA was then treated to repair both ends, after which dA was added to one reaction, followed by T-A ligation to add adaptors to both ends. Selection of the size of the adaptor-ligated DNA was then performed using DNA clean beads. PCR was subsequently performed for each sample using the P5 and P7 primers, after which the PCR products were validated. Libraries with different indices were multiplexed and loaded on an Illumina HiSeq/Illumina NovaSeq/MGI2000 instrument for sequencing using a 2 × 150 paired-end (PE) configuration according to the manufacturer’s instructions, with three technical replicates.
Preprocessing of RNA-Seq data
Low-quality reads were filtered out according to CutAdapt software (V1.9.1). The filtering process was used to produce high-quality cleaned reads by removing low-quality reads, sequences containing an unknown base N, adapter sequences, reads with more than 10% of skipped bases, and reads with an average quality score less than 20. The remaining reads were mapped onto the human reference genome (UCSC, NCBI, ENSEMBL) using the aligner software HISAT2 (v2.0.1). The transcripts in FASTA format were subsequently converted from a known gff annotation file and indexed to a reference gene file. The gene expression levels were measured using HTSeq (v0.6.1).
Differentially expressed genes (DEGs) analysis
Differential expression analysis was performed using the DESeq2 Bioconductor package, which is based on a model utilizing a negative binomial distribution. This approach incorporates data-driven prior distributions for estimates of dispersion and logarithmic fold changes. The adjusted p-value (padj) of genes, corrected with the Benjamini–Hochberg method for multiple comparison adjustment, was set at < 0.05 to identify DEGs.
Functional annotation and classification
Differentially expressed genes with an FDR less than 0.05 and a log2-fold change greater than 1.25 or less than − 1.25 were inputted into PathfindR. The KEGG pathway70,71,72, Reactome and GO databases were used for pathway analysis and functional classification. Only pathways and functional groups with p-values less than 0.05 were discussed. The active subnetworks were identified in a Biogrid protein‒protein interaction network and then subjected to pathway enrichment analysis in accordance with the database.
Transcription factor analysis
The sericin treatment group included a list of DEGs enriched with transcription factor (TF) enrichment, which was determined via decoupleR. The TF regulatory network was analyzed with the meta-database OmniPath via DecoupleR. These transcription factor activities were studied based on DoRothEA, which is a comprehensive prior knowledge resource obtaining curated TFs and their downstream targets. TF activity scores were calculated from z-transformed expression values (FDR less than 0.05).
Validation of hepatic gene expression following sericin treatment
RT‒qPCR was used to validate the top 10 differentially expressed and novel genes from RNA–seq and to measure gene expression in hepatoprotective experiments. RNA was reverse transcribed using a RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. RT‒qPCR was performed using Luna® Universal qPCR Master Mix (Biolabs, USA) according to the manufacturer’s instructions. All the specific primers used were designed using Oligo 7 primer analysis software (Supplementary Table S10), and the thermal cycling conditions are provided in Supplementary Table S11. The Ct value was normalized to that of the housekeeping gene GAPDH. Relative gene expression was calculated using the 2−ΔΔCt method. In addition, melting curves were generated to confirm the specificity and consistency of the products.
Data availability
The datasets generated and analyzed during the study are available in the Gene Expression Omnibus (GEO) repository, accession number GSE229079.
Abbreviations
- A2M:
-
Alpha-2-macroglobulin
- APAP:
-
Acetaminophen
- APOB:
-
Apolipoprotein B
- ARID5B:
-
AT-rich interaction domain 5B
- CAT:
-
Catalase
- CREB1:
-
CAMP responsive element binding protein 1
- DEGs:
-
Differentially expressed genes
- FGFR1:
-
Fibroblast growth factor receptors
- GATA3:
-
GATA binding protein 3
- GO:
-
Gene Ontology
- GSH-PX:
-
Plasma glutathione peroxidase enzymes
- HCC:
-
Hepatocellular carcinoma
- HDMs:
-
Histone demethylate
- HSPA8:
-
Heat shock protein family A (Hsp70) member 8
- IR:
-
Insulin resistance
- IRS-1:
-
Insulin receptor substrate-1
- KEGG:
-
Kyoto encyclopedia of genes and genomes
- MAPK:
-
Mitogen-activated protein kinase
- MT1E:
-
Metallothionein 1E
- MT1G:
-
Metallothionein 1G
- MT2A:
-
Metallothionein 2A
- NFE2L2:
-
NFE2 like bZIP transcription factor 2
- OGT:
-
O-linked β-N-acetylglucosamine transferase
- PI3K:
-
Phosphatidylinositol-3-kinase
- POU2F1:
-
POU domain class 2 transcription factor 1
- PPIN:
-
Protein–protein interaction network
- SERPINA5:
-
Serine proteinase inhibitor clade A member 5
- SOD:
-
Superoxide dismutase
- STAT1:
-
Signal transducer and activator of transcription 1
- TFAP2C:
-
Transcription factor AP-2 gamma
- TRAF6:
-
TNF receptor associated factor 6
References
Cornelius, C. E. Clinical Biochemistry of Domestic Animals 201–257 (Elsevier, 1980).
Qu, H. et al. Hepatoprotection of pine nut polysaccharide via NRF2/ARE/MKP1/JNK signaling pathways against carbon tetrachloride-induced liver injury in mice. Food Chem. Toxicol. 142, 111490 (2020).
Kremer, M., Hines, I. N., Milton, R. J. & Wheeler, M. D. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell–mediated hepatitis. Hepatology 44, 216–227 (2006).
Adewusi, E. & Afolayan, A. J. A review of natural products with hepatoprotective activity. J. Med. Plants Res. 4, 1318–1334 (2010).
Sheweita, S., Abd El-Gabar, M. & Bastawy, M. Carbon tetrachloride-induced changes in the activity of phase II drug-metabolizing enzyme in the liver of male rats: role of antioxidants. Toxicology 165, 217–224 (2001).
Shahjahan, M., Sabitha, K., Jainu, M. & Devi, C. S. Effect of Solanum trilobatum against carbon tetra chloride induced hepatic damage in albino rats. Indian J. Med. Res. 120, 194–198 (2004).
Padamwar, M. N. & Pawar, A. P. Silk Sericin and its Applications: A Review (CSIR, 2004).
Kunz, R. I., Brancalhão, R. M. C., Ribeiro, L. F. C. & Natali, M. R. M. Silkworm sericin: Properties and biomedical applications. BioMed Res. Int. 2016, 1–19 (2016).
Aramwit, P., Palapinyo, S., Srichana, T., Chottanapund, S. & Muangman, P. Silk sericin ameliorates wound healing and its clinical efficacy in burn wounds. Arch. Dermatol. Res. 305, 585–594 (2013).
Sasaki, M., Yamada, H. & Kato, N. A resistant protein, sericin improves atropine-induced constipation in rats. Food Sci. Technol. Res. 6, 280–283 (2000).
Onsa-Ard, A. et al. Hypotensive and vasorelaxant effects of sericin-derived oligopeptides in rats. Int. Sch. Res. Not. 2013, 1–8 (2013).
Okazaki, Y. et al. Consumption of sericin reduces serum lipids, ameliorates glucose tolerance and elevates serum adiponectin in rats fed a high-fat diet. Biosci. Biotechnol. Biochem. 74, 1534–1538 (2010).
Li, Y.-G., Ji, D.-F., Chen, S. & Hu, G.-Y. Protective effects of sericin protein on alcohol-mediated liver damage in mice. Alcohol Alcohol. 43, 246–253. https://doi.org/10.1093/alcalc/agm164 (2008).
Song, C. et al. Sericin enhances the insulin-PI3K/AKT signaling pathway in the liver of a type 2 diabetes rat model. Exp. Ther. Med. 16, 3345–3352. https://doi.org/10.3892/etm.2018.6615 (2018).
Ampawong, S., Isarangkul, D. & Aramwit, P. Sericin improves heart and liver mitochondrial architecture in hypercholesterolaemic rats and maintains pancreatic and adrenal cell biosynthesis. Exp. Cell Res. 358, 301–314 (2017).
Wang, H.-D., Zhong, Z.-H., Weng, Y.-J., Wei, Z.-Z. & Zhang, Y.-Q. Degraded sericin significantly regulates blood glucose levels and improves impaired liver function in T2D rats by reducing oxidative stress. Biomolecules 11, 1255 (2021).
Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: A revolutionary tool for transcriptomics. Nat. Rev. Genet. 10, 57–63. https://doi.org/10.1038/nrg2484 (2009).
Khatoon, Z., Figler, B., Zhang, H. & Cheng, F. Introduction to RNA-Seq and its applications to drug discovery and development. Drug Dev. Res. 75, 324–330 (2014).
Tiggelman, A. et al. Localization of α2-macroglobulin protein and messenger RNA in rat liver fibrosis: Evidence for the synthesis of α2-macroglobulin within Schistosoma mansoni egg granulomas. Hepatology 23, 1260–1267 (1996).
Gangadharan, B., Antrobus, R., Dwek, R. A. & Zitzmann, N. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin. Chem. 53, 1792–1799 (2007).
Fan, M. et al. SERPINA5 promotes tumour cell proliferation by modulating the PI3K/AKT/mTOR signalling pathway in gastric cancer. J. Cell. Mol. Med. 26, 4837–4846. https://doi.org/10.1111/jcmm.17514 (2022).
Zhang, T. et al. Identification of candidate biomarkers and prognostic analysis in colorectal cancer liver metastases. Front. Oncol. 11, 652354. https://doi.org/10.3389/fonc.2021.652354 (2021).
Tong, M. et al. Evaluation of MT family isoforms as potential biomarker for predicting progression and prognosis in gastric cancer. BioMed Res. Int. 2019, 1–15 (2019).
Ullio, C. et al. Autophagy of metallothioneins prevents TNF-induced oxidative stress and toxicity in hepatoma cells. Autophagy 11, 2184–2198. https://doi.org/10.1080/15548627.2015.1106662 (2015).
Kanda, M. et al. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int. J. Oncol. 35, 477–483. https://doi.org/10.3892/ijo_00000359 (2009).
Liu, Q., Lu, F. & Chen, Z. Identification of MT1E as a novel tumor suppressor in hepatocellular carcinoma. Pathol. Res. Pract. 216, 153213. https://doi.org/10.1016/j.prp.2020.153213 (2020).
Kooistra, S. M. & Helin, K. Molecular mechanisms and potential functions of histone demethylases. Nat. Rev. Mol. Cell Biol. 13(5), 297–311 (2012).
Kim, J.-H., Nagappan, A., Jung, D. Y., Suh, N. & Jung, M. H. Histone demethylase KDM7A contributes to the development of hepatic steatosis by targeting diacylglycerol acyltransferase 2. Int. J. Mol. Sci. 22, 11085 (2021).
Tang, B. et al. Aberrant JMJD3 expression upregulates slug to promote migration, invasion, and stem cell–like behaviors in hepatocellular carcinoma. Cancer Res. 76, 6520–6532 (2016).
He, L., Yuan, H., Liang, J., Hong, J. & Qu, C. Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis. PloS One 15, e0233702 (2020).
Segil, N., Roberts, S. B. & Heintz, N. Mitotic phosphorylation of the Oct-1 homeodomain and regulation of Oct-1 DNA binding activity. Science 254, 1814–1816 (1991).
Zhong, Y. et al. POU2F1 over-expression correlates with poor prognoses and promotes cell growth and epithelial-to-mesenchymal transition in hepatocellular carcinoma. Oncotarget 8, 44082–44095 (2017).
Zhu, H. Y. et al. POU2F1 promotes growth and metastasis of hepatocellular carcinoma through the FAT1 signaling pathway. Am. J. Cancer Res. 7, 1665–1679 (2017).
Gudowska, M. et al. Serum sialic acid concentration and content in ApoB-containing lipoproteins in liver diseases. Clin. Lab. 62, 1069–1074. https://doi.org/10.7754/clin.lab.2015.151005 (2016).
Crooke, R. M. et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872–884 (2005).
Wong, B. R. et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4, 1041–1049 (1999).
Khursigara, G., Orlinick, J. R. & Chao, M. V. Association of the p75 neurotrophin receptor with TRAF6. J. Biol. Chem. 274, 2597–2600. https://doi.org/10.1074/jbc.274.5.2597 (1999).
Rohde, M. et al. Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev. 19, 570–582 (2005).
Pinzani, M. & Marra, F. Seminars in Liver Disease 397–416 (Thieme Medical Publishers, 2021).
Kirkin, V., McEwan, D. G., Novak, I. & Dikic, I. A role for ubiquitin in selective autophagy. Mol. Cell 34, 259–269 (2009).
Rautou, P.-E. et al. Autophagy in liver diseases. J. Hepatol. 53, 1123–1134. https://doi.org/10.1016/j.jhep.2010.07.006 (2010).
Yu, S. et al. Low expression of MAP1LC3B, associated with low Beclin-1, predicts lymph node metastasis and poor prognosis of gastric cancer. Tumor Biol. 37, 15007–15017. https://doi.org/10.1007/s13277-016-5383-5 (2016).
Wang, Y., Han, J., Zhou, H., Ai, S. & Wan, D. A prognosis marker dynein cytoplasmic 1 heavy chain 1 correlates with EMT and immune signature in liver hepatocellular carcinoma by bioinformatics and experimental analysis. Disease Markers 2022, 6304859. https://doi.org/10.1155/2022/6304859 (2022).
Yang, Z. et al. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. Int. J. Med. Sci. 12, 256–263. https://doi.org/10.7150/ijms.10735 (2015).
Hardivillé, S. & Hart, G. W. Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAcylation. Cell Metab. 20, 208–213 (2014).
Lynch, T. P. et al. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J. Biol. Chem. 287, 11070–11081 (2012).
Matsusue, K. et al. Hepatic CCAAT/enhancer binding protein α mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice. Mol. Endocrinol. 18, 2751–2764 (2004).
Flodby, P., Barlow, C., Kylefjord, H., Åhrlund-Richter, L. & Xanthopoulos, K. G. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein α. J. Biol. Chem. 271, 24753–24760 (1996).
Lu, G. D. et al. C/EBPα is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology 139, 632-643.e634 (2010).
Lu, G. D. et al. C/EBPα is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology 139, 632-643.e634. https://doi.org/10.1053/j.gastro.2010.03.051 (2010).
Gao, B. Cytokines, STATs and liver disease. Cell Mol. Immunol. 2, 92–100 (2005).
Hong, F. et al. Opposing roles of STAT1 and STAT3 in T cell–mediated hepatitis: Regulation by SOCS. J. Clin. Investing. 110, 1503–1513 (2002).
Kim, W.-H. et al. STAT1 plays an essential role in LPS/D-galactosamine-induced liver apoptosis and injury. Am. J. Physiol.-Gastrointest. Liver Physiol. 285, G761–G768 (2003).
Eckert, D., Buhl, S., Weber, S., Jäger, R. & Schorle, H. The AP-2 family of transcription factors. Genome Biol. 6, 1–8 (2005).
Holl, D. et al. Transgenic overexpression of Tcfap2c/AP-2gamma results in liver failure and intestinal dysplasia. PLoS One 6, e22034. https://doi.org/10.1371/journal.pone.0022034 (2011).
Wan, Y. Y. GATA3: A master of many trades in immune regulation. Trends Immunol. 35, 233–242 (2014).
Almuraikhy, S. et al. Interleukin-6 induces impairment in human subcutaneous adipogenesis in obesity-associated insulin resistance. Diabetologia 59, 2406–2416 (2016).
Al-Mansoori, L. et al. Suppression of GATA-3 increases adipogenesis, reduces inflammation and improves insulin sensitivity in 3T3L-1 preadipocytes. Cell. Signall. 75, 109735. https://doi.org/10.1016/j.cellsig.2020.109735 (2020).
Gravito-Soares, M., Gravito-Soares, E., Gomes, D. & Tomé, L. Lysosomal acid lipase: Can it be a new non-invasive serum biomarker of cryptogenic liver fibrosis and cirrhosis?. Ann. Hepatol. 18, 78–88 (2019).
Ryoo, I.-G. & Kwak, M.-K. Regulatory crosstalk between the oxidative stress-related transcription factor Nfe2l2/Nrf2 and mitochondria. Toxicol. Appl. Pharmacol. 359, 24–33. https://doi.org/10.1016/j.taap.2018.09.014 (2018).
Suzuki, T., Motohashi, H. & Yamamoto, M. Toward clinical application of the Keap1–Nrf2 pathway. Trends Pharmacol. Sci. 34, 340–346 (2013).
Karin, M. & Dhar, D. Liver carcinogenesis: From naughty chemicals to soothing fat and the surprising role of NRF2. Carcinogenesis 37, 541–546 (2016).
Wen, A. Y., Sakamoto, K. M. & Miller, L. S. The role of the transcription factor CREB in immune function. J. Immunol. 185, 6413–6419 (2010).
Zhang, X. et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc. Natl. Acad. Sci. 102, 4459–4464. https://doi.org/10.1073/pnas.0501076102 (2005).
Visavadiya, N. P., Li, Y. & Wang, S. High glucose upregulates upstream stimulatory factor 2 in human renal proximal tubular cells through angiotensin II-dependent activation of CREB. Nephron Exp. Nephrol. 117, e62–e70 (2011).
Wang, P., Deng, L., Zhuang, C., Cheng, C. & Xu, K. p-CREB-1 promotes hepatic fibrosis through the transactivation of transforming growth factor-β1 expression in rats. Int. J. Mol. Med. 38, 521–528. https://doi.org/10.3892/ijmm.2016.2630 (2016).
Wang, Q. et al. Caffeine protects against alcohol-induced liver fibrosis by dampening the cAMP/PKA/CREB pathway in rat hepatic stellate cells. Int. Immunopharmacol. 25, 340–352 (2015).
Nicod, L., Viollon, C., Regnier, A., Jacqueson, A. & Richert, L. Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells. Hum. Exp. Toxicol. 16, 28–34. https://doi.org/10.1177/0960327197016001061 (1997).
Yu, Q. et al. The protective effects of levo-tetrahydropalmatine on ConA-induced liver injury are via TRAF6/JNK signaling. Mediat. Inflamm. 2018 (2018).
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951 (2019).
Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587–D592 (2023).
Acknowledgements
This research is funded by The Second Century Fund (C2F) Chulalongkorn University, Thailand Science Research and Innovation Fund Chulalongkorn University (CU_FRB65_hea(50)_059_33_03), and The National Research Council of Thailand and Mahidol research grant, Mahidol university, Thailand.
Author information
Authors and Affiliations
Contributions
P.A., K.K., and S.A. conceived the project. J.J., N.T., and S.A. designed the experiments. J.J. and S.A. carried out lab investigation and validation. J.J. and V.N. performed transcriptome data analysis. J.J. wrote the manuscript. J.J., N.T., S.A., and P.A. revised the manuscript. All authors read and approved the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Jantaravinid, J., Tirawanchai, N., Ampawong, S. et al. Transcriptomic screening of novel targets of sericin in human hepatocellular carcinoma cells. Sci Rep 14, 5455 (2024). https://doi.org/10.1038/s41598-024-56179-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-024-56179-y
Keywords
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.